To investigate the predictive role that neonatal birth parameters of positive newborns at phenylketonuria (PKU) screening have on false-positive and positive results. We reviewed 195 newborns (115 males and 80 females) that had false-positive results between 1998 and 2001. A total of 4386 randomly selected neonates (2191 males and 2195 females) who tested normal at the rst investigation in the same period, were used as negative-controls. A total of 38 PKU neonates (17 males and 21 females) diagnosed between 1990 and 2001 were used as positive-controls.
Results:
The risk of false-positive results is higher (~48%) in females than in males. Moreover, for each 100g of body weight reduction, the risk of false positive is around 4.2% higher. The risk of con rmation increased by 39% per week of gestational age.
Conclusions:
In conclusion, our results suggest that preterm or low-birth-weight neonates recalled at the rst investigation are more likely to be due to false-positives, whereas the risk of con rmation is higher in at-term neonates. By implication, the phenylalanine cut-off value for premature or low-body-weight infants could be higher. H yperphenylalaninemia (HPA) is a metabolic disorder characterized by an elevation of blood phenylalanine concentration, detected through neonatal screening programs worldwide. The measure of phenylalanine in dried blood-spot specimens is the most suitable and inexpensive method used preferentially across the world. Newborn screening laboratories use borderline cut-off values of phenylalanine on blood-spots between 120 mmol/l (2 mg/dl) and 258 mmol/l (4.3 mg/dl) for their rst decision level of a positive test. Possible conditions associated with borderline phenylalanine concentrations in blood spots include HPA, phenylketonuria (PKU), variant forms of PKU, other metabolic diseases and false positive results. 1, 2 Since insuf cient studies are available on the relationship between neonatal birth parameters and the outcome of PKU screening tests, 3 we investigated the relationship between gender, gestational age and body growth parameters at birth and positive and false-positive results at recall PKU neonatal screening.
METHODS
We enrolled 195 newborns (115 males and 80 females) retrospectively who had had false-positive results at PKU neonatal screening during 1998-2001. A total of 4386 neonates (2191 males and 2195 females) were randomly selected, enrolling 90 neonates born per month between 1998 and 2001, and were used as negative-controls. A total of 38 PKU neonates (17 males and 21 females) diagnosed during 1990-2001 were used as positive-controls. All the subjects studied were negative at the same screening setting for hypothyroidism, galactosemia, maple syrup urine disease, glucose-6-phosphate dehydrogenase and biotinidase de ciencies.
Growth parameters (weight, length and head circumference) of each subject, obtained by standard methods from nursing personnel at birth centres, and information regarding sex, gestational age and parity were recorded on a questionnaire included on the lter paper.
Blood samples were taken between the third and fth day of life from the babies' heels, absorbed onto S&S 903 lter paper and sent from each birth centre to our neonatal screening laboratory. From 1998 onwards, blood phenylalanine concentration was measured with a uorometric multitask plate counter Wallac 1420 VICTOR F (Perkin Elmer, Finland) and the uorescent ninhydrine method (EG&G Wallac neonatal phenylalanine kit). All analytical procedures were performed according to the manufacturer's instructions. Before 1998, the PKU screening test used in our centre was bacterial inhibition assay. Quality control for PKU screening was provided by the Italian Society for Neonatal Screening.
Normally, fasting blood phenylalanine concentrations range from ~35 mmol/l to ~100 mmol/l. In our laboratory, we use a phenylalanine cut-off level of 120 mmol/l. This cut-off level increases the sensitivity of the screening test and reduces the risk of missing the diagnosis of disorders of the phenylalanine metabolism in subjects with less pronounced phenylalanine circulating levels at the rst investigation. 4 We de ned as normal a phenylalanine concentration on blood spots of 120 mmol/l. All the newborns with phenylalanine concentrations >120 mmol/l were re-tested between the ninth and 16th day of life. Subjects with normal phenylalanine concentrations ( 120 mmol/l) in this second specimen were classi ed as false-positives, those with a phenylalanine concentration >120 mmol/l as positives.
STATISTICAL ANALYSIS
Neonatal birth parameters were reported as means with standard deviations. Differences between false-positive or positive and negative newborns were analyzed by the Kruskal-Wallis test. To nd out just how predictable sex, parity, gestational age, and weight, length and head circumference were for the possibility of being false-positive or positive at the recall PKU test, we performed a multivariate logistic regression analysis with an evaluation of the model using three goodness-of-t c 2 statistics. In all analyses, a probability level of p<0.05 was used to indicate statistical signi cance. All statistical analyses were performed using SPSS v.11.0 software for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
False-positive neonates showed a mean value of phenylalanine concentration on blood spots of 186 ± 49 mmol/l (range 126-480) measured at 3.8 ± 1.2 days of life. This group of neonates was rechecked at 11.8 ± 2.2 days of life and had a mean value of phenylalanine concentration on blood-spots of 60 ± 12 mmol/l (range 6-114). Positive neonates enrolled in the study had a mean value of phenyl-alanine concentration on blood-spots of 534 ± 336 mmol/l (range 151-1210) at 3.7 ± 1.4 days of life and 916 ± 558 mmol/l (range 311-2402) at 12.1 ± 2.4 days of life. Table 1 shows sex, parity, gestational age and growth parameters in negative, false-positive and positive newborns. Comparing negatives and false-positives with the Kruskal-Wallis test, we found the false-positive group contained signi cantly more males than females (p=0.014), and that gestational age, weight and length were signicantly lower than the negative group (p<0.05 for all parameters). Surprisingly, when we compared the negative and positive groups, we found that only the gestational age was signi cantly greater in the positive group than in the negative one (p=0.008). Comparing the false-positive and positive groups, we found that gestational age was signicantly lower among false-positives than in positives (p=0.001). Tables 2 and 3 show parity, gestational age and body growth parameters for males and females, respectively, in the three groups of subjects studied. For males ( Table 2) , gestational age and weight were signi cantly lower in the false-positive group compared with the negative group. For females (Table 3) , only length was signi cantly lower among the false-positive group than in the negative group; gestational age was signi cantly higher in the positive group than in both the false-positive and the negative group.
A multivariate logistic regression analysis was performed to assess the predictive role of physical characteristics at birth, sex, gestational age and parity of false-positive (Table  4 ) on positive results ( Table 5 ). The results of this analysis suggest that sex, body weight and gestational age adjusted for height, head circumference and parity, contributed independently to predict false-positive results ( Table 4 ). In particular, the risk of false-positive results is higher (~48%) in females than in males. Moreover, for each 100g of body weight reduction, the risk of false positive is ~4.2% higher.
For babies with a birth weight lower than 2500 g (4 true positives, 28 false positives) the choice of a cut-off level of 150 µmol/l would have avoided 13/28 (46.4%) second samples without risk of missing any PKU subjects. In positive newborns (Table 5) , gestational age, adjusted for weight, height, head circumference, sex and parity, contributed independently to predict con rmation. In particular, the risk of con rmation increased by 39% for each week of gestational age.
DISCUSSION
The growing use and application of tandem mass spectrometry in neonatal screening seems to be highly justi ed 5 , as this technology can diagnose PKU with an extremely low false-positive rate through improved precision and simultaneous con rmation with the phenylalanine/tyrosine molar ratio. 6, 7 However, to date, enzymatic colorimetric phenylalanine determination in PKU screening remains an important technique for laboratory screening that is not able to cover the greater expanses of tandem mass spectrometry. 8 In our laboratory, we use a phenylalanine cut-off level of 120 mmol/l to increase the sensitivity of the screening test and to reduce the risk of missing the diagnosis of disorders of the phenylalanine metabolism in subjects with less pronounced phenylalanine circulating levels at the rst investigation. A single phenylalanine concentration measurement and the assessment of the risks of con rmation based on neonatal birth parameters could be helpful information for laboratory physicians; they should not, however, discourage efforts to con rm and carry out follow-ups for all newborns found positive. The false-negative results at PKU screening are well known and described, as they cause disability, family stress and, in some instances, litigation; 9 on the contrary, problems concerning false-positive results have been studied less although they involve both screening centres (time and money) and families (psycho-social factors). 10 Potential causes of false-positive results are immaturity of phenylalanine hydroxylase, 11, 12 liver damage, kidney disease, overeating, low birth-weight, parenteral amino-acid admini-stration, contamination of the lter card or they are traceable to a circumscribed area of the blood spots. 13 In addition, hydroxylation defects secondary to prematurity have been suggested as a cause of transient neonatal hyperphenylalaninemia, with or without hypertyrosinemia. 2, 14 Our false-positive babies showed a signi cantly lower gestational age, body-weight and length compared with negatives. In addition, we found the highest number of false positive results in males; as these subjects showed a lower gestational age and birth-weight, we feel that their reduced enzyme maturity could explain the high number of falsepositive results in this group. On the basis of multiple logistic regression analysis, low birth-weight and female sex were the best predictive variables of false-positive results. On the contrary, at-term newborns have a higher risk of being positive at con rmation tests.
In conclusion, our results suggest that preterm or lowbirth-weight neonates recalled at the rst investigation are more likely to be false-positives, whereas the risk of con rmation is higher in at-term neonates. Consequently, the phenylalanine cut-off value to use in premature or lowbody-weight infants at the screening could be higher. 
